Gallimore A, Hombach J, Dumrese T, Rammensee H G, Zinkernagel R M, Hengartner H
Institute of Experimental Immunology, Zürich, Switzerland.
Eur J Immunol. 1998 Oct;28(10):3301-11. doi: 10.1002/(SICI)1521-4141(199810)28:10<3301::AID-IMMU3301>3.0.CO;2-Q.
This study identifies instability of MHC class I/peptide complexes and intermolecular competition for MHC class I presentation as factors responsible for the subdominance of cytotoxic T lymphocyte (CTL) epitopes. This evidence is based on the characterization of a new CTL epitope derived from the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV). This epitope, peptide GP117-125 (GP117) is presented to T cells by the mouse MHC class I molecule, H-2Db. In short-term experiments induction of GP117-specific CTL by vaccination rendered C57BL/6 mice only partially resistant to infection with wild-type LCMV (LCMV-WE) but completely resistant to challenge with a previously described LCMV variant. The variant virus, LCMV-8.7B23, bears point mutations within both known LCMV-GP, H-2 Db-restricted epitopes GP33-41 (GP33) and GP276-286 (GP276) resulting in a valine to leucine change at position 35 in peptide GP33 (V35L) and an asparagine to serine change at position 280 in peptide GP276 (N280S). Although variant peptide GP33/V35L stimulates a weak CTL response, GP276/N280S does not. Elution of peptide GP117 from both LCMV-WE- and LCMV-8.7B23-infected cells revealed that the difference in the capacity of GP117-specific CTL to protect against LCMV-WE and the virus variant LCMV-8.7B23 was due to differences in the level of GP117 presentation on the surface of both types of cells. Thus, it appears that the protective capacity of CTL specific for the subdominant epitope GP117 is influenced by the extent of presentation of other immunodominant peptide epitopes present within infected cells.
本研究确定了MHC I类/肽复合物的不稳定性以及MHC I类呈递中的分子间竞争是导致细胞毒性T淋巴细胞(CTL)表位亚显性的因素。这一证据基于对源自淋巴细胞性脉络丛脑膜炎病毒(LCMV)糖蛋白(GP)的新CTL表位的表征。该表位,肽GP117 - 125(GP117)由小鼠MHC I类分子H - 2Db呈递给T细胞。在短期实验中,通过疫苗接种诱导GP117特异性CTL使C57BL/6小鼠仅对野生型LCMV(LCMV - WE)感染部分耐受,但对先前描述的LCMV变体攻击完全耐受。变体病毒LCMV - 8.7B23在两个已知的LCMV - GP、H - 2 Db限制表位GP33 - 41(GP33)和GP276 - 286(GP276)内存在点突变,导致肽GP33中第35位的缬氨酸变为亮氨酸(V35L)以及肽GP276中第280位的天冬酰胺变为丝氨酸(N280S)。虽然变体肽GP33/V35L刺激较弱的CTL反应,但GP276/N280S则不然。从LCMV - WE和LCMV - 8.7B23感染的细胞中洗脱肽GP117表明,GP117特异性CTL针对LCMV - WE和病毒变体LCMV - 8.7B23的保护能力差异是由于两种类型细胞表面GP117呈递水平的差异。因此,似乎针对亚显性表位GP117的CTL的保护能力受感染细胞内存在的其他免疫显性肽表位的呈递程度影响。